AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis

AstraZeneca’s Fasenra (benralizumab) has been granted orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of eosinophilic oesophagitis (EoE).